Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. The authors of a new article published in Acta Pharmaceutica Sinica B describe ...
Prognostic value of TP53 mutation status in metastatic triple-negative and hormone receptor-positive breast cancer using cell-free DNA genomic profiling. This is an ASCO Meeting Abstract from the 2023 ...
Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
A simplified schematic illustrating how cancer cells evade immune attack by expressing PD-L1, which binds to PD-1 on T cells and suppresses their activity. The figure also shows how immune checkpoint ...
(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...
The FDA has approved the antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd; Datroway) for adult patients with ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results